TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00205803

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
Study: NCT04314024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A and Treatment B), or under fed conditions that is within 30 minutes after start of high-fat meal (Treatment C) in period 1, 2 and 3.
Study: NCT00193011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil
Study: NCT02210988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Intervention with acupuncture
Study: NCT03611816

Intervention type: BIOLOGICAL
Intervention: Blood taken
Description: Collection of clinical data

Intervention type: BIOLOGICAL
Intervention: Blood taken
Description: Collection of clinical data

Intervention type: BIOLOGICAL
Intervention: Blood taken
Description: Collection of clinical data

Intervention type: BIOLOGICAL
Intervention: Blood taken
Description: Collection of clinical data

Intervention type: BIOLOGICAL
Intervention: Blood taken
Description: Collection of clinical data

Intervention type: GENETIC
Intervention: Blood taken
Description: Collection of DNA

Intervention type: GENETIC
Intervention: Blood taken
Description: Collection of DNA

Intervention type: GENETIC
Intervention: Blood taken
Description: Collection of DNA

Intervention type: GENETIC
Intervention: Blood taken
Description: Collection of DNA

Intervention type: GENETIC
Intervention: Blood taken
Description: Collection of DNA

Intervention type: GENETIC
Intervention: Blood taken
Description: Collection of plasma
Study: NCT03846427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib at a dose of 160 mg orally twice a day (BID)
Study: NCT03991936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 5.0 mg/mL
Description: 5.0 mg/mL intralesional injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 7.5 mg/mL
Description: 7.5 mg/mL intralesional injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 10 mg/mL
Description: 10 mg/mL intralesional injection
Study: NCT03931980

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection
Description: we perform robotic surgery using the da Vinci Robot System Si version and laparoscopic surgery to treat rectal cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection
Description: we perform robotic surgery using the da Vinci Robot System Si version and laparoscopic surgery to treat rectal cancer
Study: NCT03383250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Normal meal
Study: NCT03394781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928
Description: oral suspension daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928
Description: oral suspension daily for 28 days
Study: NCT03609502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral training
Description: the participants will be trained to perceive a non-native speech contrast

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral training
Description: the participants will be trained to perceive a non-native speech contrast
Study: NCT01387594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar puncture
Description: 2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lumbar puncture
Description: 1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
Study: NCT04618549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Anterior Approach Hemiarthroplasty
Description: Hemiarthroplasty to elderly patients with femoral neck fracture through a direct anterior approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Posterior Approach
Description: Hemiarthroplasty to elderly patients with femoral neck fracture through a mini posterior approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral approach
Description: Hemiarthroplasty to elderly patients with femoral neck fracture through a lateral approach (Hardinge)
Study: NCT00916396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dehydroepiandrosterone
Description: 100 mg of DHEA a day (50 mg twice a day) for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100 mg of Placebo a day (50 mg twice a day) for six weeks
Study: NCT03797885

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment is administered to the participants for this study

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment is administered to the participants for this study
Study: NCT04655846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing intervention outcome: Breastfeeding Counseling (5244)
Description: Educational sessions: The nursing professional will carry out 1 educational session per week, for 4 weeks; each lasting between 45 and 60 minutes. The topics that make up each of the activities are:~1. Educational Session: Awareness towards the process of breastfeeding. Inform about the psychological and physiological benefits of breastfeeding.~2. Educational session: Teach the composition of breast milk. Teach the baby's correct alignment, latch, and areolar understanding of the breast. Instruct on breastfeeding positions.~3. Educational Session: Explain the extraction and conservation of breast milk.~4. Educational session: Explain the signs, symptoms, and management strategies for duct obstruction, mastitis, and nipple trauma. Talk about your needs for rest, hydration, and diet during breastfeeding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nursing education about maternal care and usual education in maternity preparation course
Description: Educational intervention by a nursing professional on the provision of adequate care at the level of growth and development in infants under one year of age, activities not related to the breastfeeding process
Study: NCT01319045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
Study: NCT04245657

Intervention type: OTHER
Intervention: Tissue Dielectric Constant Measurement
Description: Sub-tissue fluid proportion will be evaluated via Moisture Meter D (Delfin Technologies, Kuopio, Finland) on both upper extremity (right and left) in predefined reference points on volar side (6 cm distal and 8 cm proximal points from cubital crease, 10 cm inferior side point from axilla and dorsal point of web space in the hand) by using four different probes which can assess 0.5 mm, 1.5 mm, 2.5 mm and 5.0 mm depth. Values taken by 2.5 mm depth probe will be used to calculate the ratio (affected side TDC value/Unaffected side TDC value) to stage lymphedema severity along with the International Society of Lymphology staging system. This device mainly aims to assess the dielectric constant of tissues which is related to the amount of tissue water. In the case of pre-lymphedema or lymphedema, one can assess objectively regarding sub-tissue fluid changes via this device. Triplicate measurements will be taken for each reference point.

Intervention type: OTHER
Intervention: Muscle strength measurement
Description: Participants' muscle strength of shoulder flexion, abduction, and elbow flexion will be assessed via Handheld digital dynamometer (Lafayette Manual Muscle Tester, Model 01165, LaFayette Instruments, NY, USA). Both upper extremities will be assessed three times and the average value will be recorded.
Study: NCT02970422

Intervention type: OTHER
Intervention: Patient Survey
Description: Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.

Intervention type: OTHER
Intervention: Patient Survey
Description: Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
Study: NCT03902015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nuance Phone case
Description: participants will receive a phone (iPhone) with the Nuance Phone case and a designated app required for the use of the device. Participants will first undergo hearing test via the app, and afterwards (in case they are not excluded based on hearing status), will receive a introduction on how to use the app and the device. Before starting the clinical trial, children will undergo three adjustments days in which they will practice using the device in school. During this period the researchers will make sure that the participants are adapting to the use of the device, and in any case there is a problem, will be able to contact a representative of Nuance Hearing who will be available to support technical issues.
Study: NCT04213469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
Description: Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1
Study: NCT02522429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Intensity Focused Ultrasound Device
Description: Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
Study: NCT00294671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diflunisal
Description: given twice daily for 24 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance given twice daily for 24 months
Study: NCT02259725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03689049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPIDER
Description: The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
Study: NCT02236325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT Brief Suicide Intervention
Description: Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
Study: NCT02964273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan spray-dried, immediate release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan spray-dried, immediate release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan spray-dried, immediate release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolvaptan Matching-placebo
Description: Tolvaptan matching-placebo tablets
Study: NCT04359524

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (1200 IU/30µg)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oil capsule
Study: NCT03372720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Undergo fractional CO2 laser therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intervention
Description: Undergo sham laser therapy
Study: NCT02345408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX872-B
Description: Tablets (oral administration)
Study: NCT01132950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Didactic Educational Counseling
Description: Participant will watch an educational video while in jail and a second educational video at 3 months post release.
Study: NCT00205803

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-Valent Pneumococcal Conjugate Vaccine (7vPnC)
Study: NCT00928161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexlansoprazole
Description: Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
Study: NCT05854810

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fertilized embryo Insertion
Description: insertion of single fertilized embryo through IVF
Study: NCT00570466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Games
Description: Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
Study: NCT05854810

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fertilized embryo Insertion
Description: insertion of double fertilized embryo through IVF
Study: NCT04359511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone 0.7 mg/kg/d (PO)
Study: NCT02319460

Intervention type: BIOLOGICAL
Intervention: Kcentra®
Description: Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.

Intervention type: BIOLOGICAL
Intervention: Plasma

Intervention type: BIOLOGICAL
Intervention: Plasma
Study: NCT00570466

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Web and DVD knowledge
Description: Web and DVD based knowledge games
Study: NCT02162225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beet juice (Unbeetable)
Description: Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28.
Study: NCT03582592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fluid Distribution Timetable
Description: It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
Study: NCT05249842

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometric evaluation
Description: Evaluation of: forced vital capacity (FVC),, FEV1', FEV 1/FVC, FEF 25-75

Intervention type: DIAGNOSTIC_TEST
Intervention: Physical component summary
Description: Evaluation of the physical component summary of SF-36 quality of life

Intervention type: DIAGNOSTIC_TEST
Intervention: 6MWT
Description: 6 minute walk test
Study: NCT04017793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: Structured 8-week training program teaching about increased mindfulness strategies and gentle stretching.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Group
Description: 8-weekly group discussion meetings reviewing relaxation techniques and other stress reduction strategies with an emphasis on social support.
Study: NCT02379260

Intervention type: OTHER
Group type: OTHER
Intervention: Interview with a sociologist

Intervention type: OTHER
Group type: OTHER
Intervention: Interview with a sociologist
Study: NCT00698113

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.~Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Journaling
Description: Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Journaling
Description: Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
Study: NCT02035046

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Samplings of blood

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sampling of urine

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measure of the blood pressure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: glycemia test
Study: NCT02492412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE 10

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Restasis
Study: NCT00731614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy and Mirror Retraining
Description: Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy
Description: Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror retraining
Description: Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain